According to the unmet medical needs of patients with tumors, tumor therapeutic antibodies, including trastuzumab (anti-human epidermal growth factor receptor 2 [HER2] therapy) and cetuximab (anti-EGFR therapy), were developed and clinically approved as treatments for a solid carcinoma and a broad range of cancers, respectively [41,42]. Here, ERBB2 is linked to neoplasm.